<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-03-16T18:33:49Z</responseDate><request verb="GetRecord" identifier="oai:uvadoc.uva.es:10324/83315" metadataPrefix="qdc">https://uvadoc.uva.es/oai/request</request><GetRecord><record><header><identifier>oai:uvadoc.uva.es:10324/83315</identifier><datestamp>2026-03-03T20:01:15Z</datestamp><setSpec>com_10324_1181</setSpec><setSpec>com_10324_931</setSpec><setSpec>com_10324_894</setSpec><setSpec>col_10324_1387</setSpec></header><metadata><qdc:qualifieddc xmlns:qdc="http://dspace.org/qualifieddc/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
<dc:title>Resting-state gamma activity as a discriminative marker for cognitive subtypes in psychosis</dc:title>
<dc:creator>Osorio Iriarte, María Emma</dc:creator>
<dc:creator>Díez Revuelta, Álvaro</dc:creator>
<dc:creator>Fernández Linsenbarth, Ines</dc:creator>
<dc:creator>Arjona Valladares, Antonio</dc:creator>
<dc:creator>Beño Ruiz De La Sierra, Rosa María</dc:creator>
<dc:creator>Roig Herrero, Alejandro</dc:creator>
<dc:creator>Martínez Sánchez, José María</dc:creator>
<dc:creator>Sobrino Conde, Luis</dc:creator>
<dc:creator>Molina Rodríguez, Vicente</dc:creator>
<dcterms:abstract>Background and hypothesis: Schizophrenia and other psychotic disorders exhibit significant clinical and cognitive&#xd;
heterogeneity, challenging diagnosis and treatment. Given indications of widespread cortical hyperactivity and&#xd;
dysregulation of neural oscillations in schizophrenia, investigating resting-state activity is highly relevant. This&#xd;
study examined resting-state EEG alterations across previously defined cognitive subtypes within the psychosis&#xd;
spectrum.&#xd;
Study design: We analyzed resting-state EEG data from 141 psychosis patients (64 chronic schizophrenia, 40 first-&#xd;
episode schizophrenia, 37 bipolar disorder) and 80 healthy controls. Patients were a priori classified into two&#xd;
distinct cognitive subgroups: Cluster 1 (severe impairment, n = 47) and Cluster 2 (moderate impairment, n =&#xd;
94).&#xd;
Study results: Both patient clusters exhibited increased spectral power across most frequency bands compared to&#xd;
healthy controls. Notably, the more severely impaired Cluster 1 showed significantly higher power in the&#xd;
gamma-1 band (30–45 Hz) compared to Cluster 2. Furthermore, in Cluster 1, a significant positive correlation&#xd;
was found between resting-state gamma-1 power and positive symptom scores.&#xd;
Conclusions: These results support our hypothesis of distinctive basal hyperactivation linked to the cognitive&#xd;
profile, suggesting that altered intrinsic brain activity, particularly gamma-1 hyperactivation, may underlie&#xd;
cognitive heterogeneity in psychosis. This also suggests that gamma-1 band hyperactivation at rest serves as a&#xd;
distinct neurophysiological marker differentiating both subgroups. Our findings highlight the importance of&#xd;
subdivision approaches to identify more homogeneous patient subgroups and emphasize the potential of resting-&#xd;
state gamma activity as a precise biomarker for specific symptom dimensions and personalized treatment&#xd;
strategies.</dcterms:abstract>
<dcterms:dateAccepted>2026-03-03T12:22:19Z</dcterms:dateAccepted>
<dcterms:available>2026-03-03T12:22:19Z</dcterms:available>
<dcterms:created>2026-03-03T12:22:19Z</dcterms:created>
<dcterms:issued>2026</dcterms:issued>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:identifier>Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2026, vol. 145, p. 111646</dc:identifier>
<dc:identifier>0278-5846</dc:identifier>
<dc:identifier>https://uvadoc.uva.es/handle/10324/83315</dc:identifier>
<dc:identifier>10.1016/j.pnpbp.2026.111646</dc:identifier>
<dc:identifier>111646</dc:identifier>
<dc:identifier>Progress in Neuro-Psychopharmacology and Biological Psychiatry</dc:identifier>
<dc:identifier>145</dc:identifier>
<dc:language>eng</dc:language>
<dc:relation>https://www.sciencedirect.com/science/article/pii/S0278584626000424</dc:relation>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
<dc:rights>© 2026 The Author(s)</dc:rights>
<dc:rights>Atribución 4.0 Internacional</dc:rights>
<dc:publisher>Elsevier</dc:publisher>
</qdc:qualifieddc></metadata></record></GetRecord></OAI-PMH>